ATE476183T1 - Verfahren zur behandlung von soliden tumoren einschliesslich der verabreichung einer kombination mit imatinib und einem effluxpumpenhemmer - Google Patents

Verfahren zur behandlung von soliden tumoren einschliesslich der verabreichung einer kombination mit imatinib und einem effluxpumpenhemmer

Info

Publication number
ATE476183T1
ATE476183T1 AT06754477T AT06754477T ATE476183T1 AT E476183 T1 ATE476183 T1 AT E476183T1 AT 06754477 T AT06754477 T AT 06754477T AT 06754477 T AT06754477 T AT 06754477T AT E476183 T1 ATE476183 T1 AT E476183T1
Authority
AT
Austria
Prior art keywords
combination
imatinib
solid tumors
pump inhibitor
efflux pump
Prior art date
Application number
AT06754477T
Other languages
English (en)
Inventor
Sebastien Bihorel
Gerhard Gross
Michel Lemaire
Gian Camenisch
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0512843A external-priority patent/GB0512843D0/en
Priority claimed from GB0602264A external-priority patent/GB0602264D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE476183T1 publication Critical patent/ATE476183T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06754477T 2005-06-23 2006-06-21 Verfahren zur behandlung von soliden tumoren einschliesslich der verabreichung einer kombination mit imatinib und einem effluxpumpenhemmer ATE476183T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0512843A GB0512843D0 (en) 2005-06-23 2005-06-23 Organic compounds
GB0602264A GB0602264D0 (en) 2006-02-03 2006-02-03 Organic compounds
PCT/EP2006/005960 WO2006136391A2 (en) 2005-06-23 2006-06-21 Treatment of solid tumor disease with combinations comprising imatinib and an efflux pump inhibitor

Publications (1)

Publication Number Publication Date
ATE476183T1 true ATE476183T1 (de) 2010-08-15

Family

ID=36763157

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06754477T ATE476183T1 (de) 2005-06-23 2006-06-21 Verfahren zur behandlung von soliden tumoren einschliesslich der verabreichung einer kombination mit imatinib und einem effluxpumpenhemmer

Country Status (6)

Country Link
US (1) US20080214445A1 (de)
EP (1) EP1951243B1 (de)
JP (1) JP2008546729A (de)
AT (1) ATE476183T1 (de)
DE (1) DE602006015994D1 (de)
WO (1) WO2006136391A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2156188B1 (de) * 2007-03-28 2021-05-05 University of Southern California Induktion differentieller stressresistenz und verwendungen davon
WO2009083042A1 (en) * 2007-12-31 2009-07-09 Olaf Van Tellingen Methods and means for the treatment of cancer
WO2011018090A1 (en) 2009-08-11 2011-02-17 Andersen Stig Uggerhoej Predictive marker for hydroxyurea resistance

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2748206B1 (fr) * 1996-05-06 1998-07-31 Solvay Pharma Utilisation de bromure de pinaverium dans la prevention des phenomenes proliferatifs des cellules du tractus hepatodigestif et des maladies qui en resultent
ITMI992711A1 (it) * 1999-12-27 2001-06-27 Novartis Ag Composti organici
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
WO2004032925A1 (en) * 2002-10-11 2004-04-22 Novartis Ag Use of imatinib (glivec, sti-571) to inhibit breast cancer resistance protein (bcrp)-mediated resistance to therapeutic agents
GB0311971D0 (en) * 2003-05-23 2003-06-25 Novartis Ag Organic compounds
WO2006012958A2 (en) * 2004-07-01 2006-02-09 The Netherlands Cancer Institute Combination comprising a bcrp inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide

Also Published As

Publication number Publication date
WO2006136391A2 (en) 2006-12-28
JP2008546729A (ja) 2008-12-25
WO2006136391A3 (en) 2007-03-15
US20080214445A1 (en) 2008-09-04
DE602006015994D1 (de) 2010-09-16
EP1951243A2 (de) 2008-08-06
EP1951243B1 (de) 2010-08-04

Similar Documents

Publication Publication Date Title
CY2021019I2 (el) Παραγωγα ν4-φαινυλ-κιναζολινο-4-αμινης και σχετικες ενωσεις ως αναστολεις υποδοχεα κινασης τυροσινης τυπου i erbb για τη θεραπεια υπερπολλαπλασιαστικων ασθενειων
CL2020003329A1 (es) Moléculas de ácido nucleico para la reducción de arnm de papd5 o papd7 para tratar la infección por hepatitis b (divisional solicitud no. 3561-2018)
EP3873462A4 (de) Verfahren zur behandlung von krebs bei biomarker-identifizierten patienten mit nicht-kovalenten hemmern der cyclin-abhängigen kinase 7 (cdk7)
PE20220141A1 (es) Inhibidores de la proteina tirosina fosfatasa
EP4467143C0 (de) Verfahren zur herstellung von 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitril
EA201991697A1 (ru) Сульфоксиминовые ингибиторы гликозидазы
DE60219617D1 (de) Kombination von n- 5- 4-(4-methyl-piperazino-methyl)-benzoylamido -2-methylphenyl -4-(3-pyridil)-2pyrimidine-amin mit einem biphosphonat
ATE499097T1 (de) Monozyklische heterozyklen als kinase-hemmer
EP4010080C0 (de) Heterocyclische verbindungen zur verwendung bei der behandlung von krebs
DE602004022187D1 (de) 4-(pyrazol-3-ylamino)pyrimidinderivate zur verwendung bei der behandlung von krebs
ATE521354T1 (de) Kombination aus imatinib und einem histondeacetylase-hemmer zur behandlung von leukämie
ATE447957T1 (de) Verfahren zur unterdrückung einer immunantwort oder zur behandlung von proliferativen erkrankungen
ATE554087T1 (de) Neue kinaseinhibitoren
DE602007010303D1 (de) Verwendung von 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin--2,6-dion zur behandlung von mantelzelllymphomen
IL286983A (en) Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor
ATE339197T1 (de) 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3- 4-pyrimindin-3-yl)pyrimidin-2-yl-amino)phenyl)- benzamide zur behandlung von ang-ii vermittelt krankheiten
DE602004021435D1 (de) Injizierbare zusammensetzung zur behandlung von krebs
BR0207649A (pt) Combinação compreendendo um inibidor de transdução de sinal e um derivado de epotilona
ATE424208T1 (de) Proteinkinaseinhibitoren
CY1110027T1 (el) Συνδυασμος ενωσεων πυριμιδυλαμινοβενζαμιδης και ιματινιβης για τη θεραπεια ή την προληψη των νεοπλασματικων ασθενειων
DE602006015994D1 (de) Verfahren zur behandlung von soliden tumoren einschliesslich der verabreichung einer kombination mit imatinib und einem effluxpumpenhemmer
ECSP066656A (es) COMBINACIÓN DE (a) N-{5-[4-(4-METIL-PIPERAZINO-METIL)-BENZOILAMIDO]2-METILFENIL}-4-(3-PIRIDIL)-2-PIRIMIDINA-AMINA Y (b) POR LO MENOS UN INHIBIDOR DE HIPUSINACIÓN Y EL USO DE LA MISMA
DE60319211D1 (de) Kombination von glivec (sti571) mit einem cyclinabhängigen kinaseinhibitoren, ins besonders flavopiridol, zur behandlung von krebs
DE102004015099A1 (de) Imidazolderivate
ATE348614T1 (de) 2-(4-(phenylamino)-piperidin-1-yl)-n-phenyl- acetamid derivate und verwandte verbindungen als neuropeptid y5 (npy5) liganden zur behandlung von fettleibigkeit

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties